Reduced dosage of bevacizumab in treatment of vestibular schwannomas in patients with neurofibromatosis type 2

European Archives of Oto-Rhino-Laryngology

Volumn 272, Issue 12, 2015, Pages 3857-3860

  Farschtschi, Said ^a   Kollmann, Philipp ^a   Dalchow, Carsten ^a   Stein, Alexander ^a   Mautner, Victor Felix ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Bevacizumab; Dose reduction; Neurofibromatosis; NF2; VEGF; Vestibular schwannoma

Indexed keywords

BEVACIZUMAB; ANGIOGENESIS INHIBITOR;

ACOUSTIC NEURINOMA; ADULT; ANTIANGIOGENIC THERAPY; CANCER DIAGNOSIS; CANCER THERAPY; CASE REPORT; DRUG DOSE REDUCTION; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; LETTER; MALE; NEUROFIBROMATOSIS TYPE 2; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEINURIA; PURE TONE AUDIOMETRY; TREATMENT OUTCOME; TUMOR GROWTH; TUMOR VOLUME; COMPLICATION; DOSE RESPONSE; HEARING LOSS; NEUROMA, ACOUSTIC;

ADULT; ANGIOGENESIS INHIBITORS; BEVACIZUMAB; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEARING LOSS; HUMANS; MALE; NEUROFIBROMATOSIS 2; NEUROMA, ACOUSTIC;

EID: 84946497512     PISSN: 09374477     EISSN: 14344726     Source Type: Journal    
DOI: 10.1007/s00405-015-3604-y     Document Type: Letter

References (13)

1. Evans DGR, Moran A, King A et al (2005) Incidence of vestibular schwannoma and neurofibromatosis 2 in the North West of England over a 10-year period: higher incidence than previously thought. Otol Neurotol 26(1):93–97
2. Plotkin SR, Stemmer-Rachamimov AO, Barker FG et al (2009) Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N Engl J Med 361(4):358–367. doi:10.1056/NEJMoa0902579
3. Mautner V, Nguyen R, Knecht R et al (2010) Radiographic regression of vestibular schwannomas induced by bevacizumab treatment: sustain under continuous drug application and rebound after drug discontinuation. Ann Oncol 21(11):2294–2295. doi:10.1093/annonc/mdq566
4. Mautner V, Nguyen R, Kutta H et al (2010) Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2. Neuro Oncol 12(1):14–18. doi:10.1093/neuonc/nop010
5. Eminowicz GK, Raman R, Conibear J et al (2012) Bevacizumab treatment for vestibular schwannomas in neurofibromatosis type two: report of two cases, including responses after prior gamma knife and vascular endothelial growth factor inhibition therapy. J Laryngol Otol 126(1):79–82. doi:10.1017/S0022215111002805
6. Plotkin SR, Merker VL, Halpin C et al (2012) Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients. Otol Neurotol 33(6):1046–1052. doi:10.1097/MAO.0b013e31825e73f5
7. Hawasli AH, Rubin JB, Tran DD et al (2013) Antiangiogenic agents for nonmalignant brain tumors. J Neurol Surg B Skull Base 74(3):136–141. doi:10.1055/s-0033-1338262
8. Plotkin SR, Albers AC, Babovic-Vuksanovic D et al (2014) Update from the 2013 international neurofibromatosis conference. Am J Med Genet A 164(12):2969–2978. doi:10.1002/ajmg.a.36754
9. Alanin MC, Klausen C, Caye-Thomasen P et al (2014) The effect of bevacizumab on vestibular schwannoma tumour size and hearing in patients with neurofibromatosis type 2. Eur Arch Otorhinolaryngol. doi:10.1007/s00405-014-3398-3
10. Slusarz KM, Merker VL, Muzikansky A et al (2014) Long-term toxicity of bevacizumab therapy in neurofibromatosis 2 patients. Cancer Chemother Pharmacol 73(6):1197–1204. doi:10.1007/s00280-014-2456-2
11. Gordon MS, Margolin K, Talpaz M et al (2001) Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 19(3):843–850
12. Gutmann DH, Aylsworth A, Carey JC et al (1997) The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA 278(1):51–57
13. Plotkin SR, Halpin C, Blakeley JO et al (2009) Suggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannoma. J Neurooncol 93(1):61–77. doi:10.1007/s11060-009-9867-7